Trial Profile

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capivasertib (Primary) ; Cediranib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Carcinoma; Endometrial cancer
Focus Therapeutic Use

28 Jan 2025 Planned End Date changed from 31 Dec 2024 to 24 Jan 2026.
27 Jun 2024 The dosing routine of oral cediranib maleate is changed from twice a day (BID) for 28 days to once a day (QD) for days 1-5 per week.
11 Apr 2024 Planned End Date changed from 15 Apr 2024 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com